HEPTARES THERAPEUTICS
Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets. The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, Stabilised Receptors), overcoming a major limiting factor to the development of new drugs targeting this group.
HEPTARES THERAPEUTICS
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2007-01-01
Address:
Welwyn Garden City, Hertford, United Kingdom
Country:
United Kingdom
Website Url:
http://www.soseiheptares.com
Total Employee:
11+
Status:
Active
Contact:
+441707358628
Total Funding:
61.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Content Delivery Network Google Universal Analytics Font Awesome
Current Advisors List
Board_member
Board_member
Board_member
Advisor
Board_member
Current Employees Featured
Daniel Grau President @ Heptares Therapeutics
President
Malcolm Weir Founder & CEO @ Heptares Therapeutics
Founder & CEO
2007-07-01
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-11-29 | G7 Therapeutics | G7 Therapeutics acquired by Heptares Therapeutics | 12 M CHF |
| 2014-12-26 | JITSUBO | JITSUBO acquired by Heptares Therapeutics | N/A |
Investors List
Teva Pharmaceutical Industries
Teva Pharmaceutical Industries investment in Venture Round - Heptares Therapeutics
Takeda Ventures
Takeda Ventures investment in Series B - Heptares Therapeutics
Clarus Ventures
Clarus Ventures investment in Series B - Heptares Therapeutics
Stanley Family Foundation
Stanley Family Foundation investment in Series B - Heptares Therapeutics
Clarus Ventures
Clarus Ventures investment in Series A - Heptares Therapeutics
MVM Life Science Partners
MVM Life Science Partners investment in Series A - Heptares Therapeutics
Novartis Venture Fund
Novartis Venture Fund investment in Series A - Heptares Therapeutics
MVM Life Science Partners
MVM Life Science Partners investment in Seed Round - Heptares Therapeutics
Official Site Inspections
http://www.soseiheptares.com Semrush global rank: 65.05 K Semrush visits lastest month: 1.75 M
- Host name: 76.76.21.21
- IP address: 76.76.21.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Heptares Therapeutics"
Sosei Heptares - Craft
Oct 29, 2024 Sosei Heptares has 5 employees across 4 locations and ¥12.77 b in annual revenue in FY 2023. See insights on Sosei Heptares including office locations, competitors, …See details»
Nxera Pharma | LinkedIn
Nxera Pharma | LinkedInのフォロワー数11,031人。Nxera Pharma is a technology powered biopharma company. | Nxera Pharma (formerly Sosei Heptares) is a technology powered …See details»
Sosei Heptares Confirms Re-election of its Board and Executive ...
Mar 27, 2024 Tokyo, Japan and Cambridge, UK, 27 March 2024 – Sosei Group Corporation (“the Company”; TSE: 4565) announces that the re-election of its Board of Directors and …See details»
Sosei Heptares Operational Highlights and Consolidated Results …
Hironoshin.Nomura@SoseiHeptares.com . Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures +81 (0)3 5210 3399 | IR@SoseiHeptares.com . Citigate Dewe …See details»
Sosei Heptares Operational Highlights and Consolidated
Feb 13, 2024 Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational...See details»
Sosei Heptares enters into multi -target research collaboration and ...
Development and enabling the company to become a truly world-class and global organization.” – ENDS – About Sosei Heptares ... IR@SoseiHeptares.com. Citigate Dewe Rogerson (for …See details»
Sosei Group - Overview, News & Similar companies - ZoomInfo
Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals Tokyo, Japan and Cambridge, UK, 6 March 2024 – Sosei Group Corporation (“Sosei …See details»
Sosei Heptares announces New Board Director Appointment and …
Focused organization we now have in place, Sosei Heptares is well placed to deliver on its goals and generate value for its shareholders.” – ENDS – About Sosei Heptares ...See details»
Sosei Heptares - LinkedIn
Sosei Heptares | 5,964 followers on LinkedIn. The world leader in GPCR targeted medicine design and development | We are an international biopharmaceutical group focused on the …See details»
Sosei Group Corporation (d/b/a Sosei Heptares). (10/10/23). "Press ...
BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization) EuropaBio aisbl – the European Association of Bioindustries; BioIndustry Association (BIA) …See details»
Sosei Heptares - VentureRadar
Website: https://www.soseiheptares.com/ Develops innovative biopharmaceuticals targeting GPCR with proprietary StaR® technology, focusing on neurology, immunology ...See details»
Our life’s work, is life itself - Nxera Pharma
At Nxera Pharma, our mission is to accelerate the development of life-changing medicines by investing in science and technology. Our world-leading and proprietary NxWave™ platform …See details»
Sosei Heptares Operational Highlights and Consolidated Results …
Feb 13, 2024 Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities …See details»
Sosei Heptares Receives Approval for Change of Market Listing …
Mar 8, 2023 Tokyo, Japan and Cambridge, UK, 8 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused …See details»
Sosei Heptares Operational Highlights and Consolidated Results …
SoseiHeptares@citigatedewerogerson.com. Forward-looking statements This press release contains forward-looking statements, including statements about the discovery, development …See details»
Sosei Heptares and Verily nominate first G-protein-coupled …
October 4, 2023 - Sosei Group Corporation ("Sosei Heptares"; TSE: 4565) and Verily, an Alphabet precision health technology company, today announced the successful validation …See details»
Boehringer Ingelheim and Sosei Heptares join forces to develop …
Mar 11, 2024 Ingelheim, Germany, Tokyo, Japan and Cambridge, UK, 11 March 2024 – Today, Boehringer Ingelheim and Sosei Group Corporation (“Sosei Heptares”; TSE: 4565) announced …See details»
Sosei Heptares and Verily will collaborate to generate novel drug ...
Jan 6, 2022 +44 (0)203 928 6900 | SoseiHeptares@medistrava.com. Verily Media Contact. Steven Cooper, Head of Media Relations 646-358-2765 | sjcoop@verily.com. Sosei Group …See details»
Sosei Heptares reports progress with Pfizer as multi-target ...
May 14, 2019 IR@SoseiHeptares.com . Citigate Dewe Rogerson (for international media) Mark Swallow, David Dible +44 (0)20 7638 9571 . SoseiHeptares@citigatedewerogerson.com . …See details»
Sosei Heptares Webinar Presentation for FY2022 Financial Results
+44 (0)203 928 6900 | SoseiHeptares@medistrava.com Forward-looking statements This press release contains forward-looking statements, including statements about the discovery, …See details»